AzTrials
AzTrials

AsthmaNCT00584051

Examination of the Role of Atrial Natriuretic Peptide Polymorphisms in Allergic Rhinitis and Asthma Severity

An observational study of Asthma and Allergic Rhinitis, run by University of South Florida at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Asthma is an inflammatory condition of the airways in the lungs that results in obstruction of airflow in those with the condition. The disease continues to be a major worldwide health care problem and its prevalence continues to increase annually. In 2005, 20 million people were diagnosed with asthma. Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Asthma, Allergic Rhinitis
How many people
90 participants
Where
1 siteUnited States
Study dates
Oct 2007to Oct 2009
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: The study will include three groups; an asthma group, an allergic rhinitis group, and a healthy control group. Participants will be between 18-40 years of age and will meet inclusion/exclusion criteria outlined below. The study will continue for a total of 1 year. Study subjects will keep a diary of symptoms using a validated asthma subjective questionnaire (Juniper). Serum levels of atrial natriuretic peptide and serum IgE, will be obtained at the initial visit and then at regular intervals depending on the study group (table 1).

Who may be able to join

  • Subjects between 18-40 years of age
  • History of asthma diagnosed by a physician
  • Have a physician documented diagnosis of allergic disease based on detection of sensitivity by either skin prick testing or RAST,
  • Have a decreased FEV1 with 12% improvement in FEV1 documented within 12 weeks
  • Subjects between ages of 18-40
  • Have a physician documented history of allergic rhinitis based on prior skin prick testing or a positive RAST test.
Show all 9Show fewer
  • Subjects between 18-40 years of age
  • FEV1 greater than 80% predicted
  • No history of wheezing or allergies

Who cannot join

  • Use of systemic corticosteroids 4 weeks prior to initial visit
  • Use of antihistamines 7 days prior to initial visit
  • Respiratory infection 2 weeks prior to initial visit
  • History of Xolair use or immunotherapy
  • Current smoking, alcohol, or substance abuse
  • Patients with primary immunodeficiency
Show all 10Show fewer
  • Patients currently on immunosuppressive therapy
  • Unable to perform pulmonary function testing
  • History of congestive heart failure
  • Current cancer diagnosis or undergoing cancer therapy

Trial locations and contacts

1 site in 1 country.

United States1 site
  • USF

    Tampa, Florida, 33613

Other trials in United States

About this study

Official title: The Purpose of This Study is to Examine the Role of Atrial Natriuretic Peptide Polymorphisms in Allergic Rhinitis and Asthma Severity

Asthma is an inflammatory condition of the airways in the lungs that results in obstruction of airflow in those with the condition. The disease continues to be a major worldwide health care problem and its prevalence continues to increase annually. In 2005, 20 million people were diagnosed with asthma. The disease causes significant morbidity and accounts for 5,000 deaths annually. Between 1980 and 1994 the prevalence of asthma increased 74% in the United States and, in children under age 5, the prevalence increased by 160%. The allergic etiology of airway inflammation associated with asthma is established. Bronchial washings of asthmatic subjects are most often characterized by eosinophils, mast cells, and cytokines that are associated with the Th2 (allergic) phenotype. Similarly, IgE plays a pivotal role in airway inflammation of asthmatic subjects when allergens that cross-link IgE bound to mast cells in the airways cause the release of histamine and other inflammatory mediators. The association of asthma and the IgE mediated allergic phenotype is well established and up to 70% of asthmatics also suffer from allergic disease.

Adequately treated asthma often has minimal impact of quality of life but diagnosis and proper treatment is often delayed, resulting in increased missed school days, emergency room visits, and otherwise preventable degradation in quality of life. It would therefore be highly useful to identify a biomarker that can be used to assist in the diagnosis of asthma or to identify subjects at higher risk of developing allergic disease or asthma in the future. Efforts at identifying a genetic marker for the early diagnosis of asthma have been unsuccessful, mainly due to the complexity of the pathogenesis of the disease.

Read more

Atrial natriuretic factor is a pro-hormone precursor for 4 natriuretic peptide hormones including atrial natriuretic peptide (ANP). ANP's effects on the cardiovascular system are well characterized. Less well understood is the role these hormones play in immune regulation.

Recent studies have demonstrated a role for ANP in the regulation of immune function: ANP induces release of histamine from mast cells and macrophages, stimulates migration of neutrophils, enhances the cytotoxic activity of natural killer (NK) cells, and stimulates TNF-β production. Human dendritic cells express ANP receptors (GC-a) which polarize CD4+ cells towards a Th2 phenotype.

Since allergic rhinitis and asthma are associated with a Th2 phenotype, it is possible that elevated levels of ANP can be used to predict asthma severity or to predict future predilection to atopic disease.

There are a number of ANP gene polymorphisms that have been studied and found to be associated with renal disease, heart disease, hypertension and diabetes. Several studies have investigated the potential role of these polymorphisms in cardiovascular disease and have found association between polymorphisms of the ANP gene and left ventricular remodeling, hypertension, renal disease, diabetes, and increased risk of ischemic stroke. To our knowledge, no studies evaluating the role of ANP polymorphisms in allergic disease have been performed.

The goal of this research proposal is to evaluate whether ANP levels can be utilized to assist in diagnosis of asthma and in the prediction of asthma severity. Additionally, we will investigate the potential effect of polymorphisms in the ANP gene on asthma severity and thus serve as a useful genetic marker to predict future risk of atopy and asthma.

Keywords
Control group
Medical subject headings
Asthma, Rhinitis, Allergic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT00584051
Study groupRoleWhat they receive
1Not described
2Not described
3Not described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To determine if an overproduction of ANP is associated with atopy and asthma.

    Measured: 1 YEAR

Secondary outcomes (1)
  1. To determine whether polymorphisms in the ANP gene contribute to the pathogenesis of the allergic condition or asthma.

    Measured: 1YEAR

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Jan 2008 (estimated)
  2. Study startOct 2007
  3. Primary completionOct 2009
  4. Study completionOct 2009

Why it stopped: investigator closed study

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00584051
Sponsor's protocol ID
PURCELL
Status last verified
Oct 2018
First submitted
21 Dec 2007
Last updated
4 Oct 2018
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Asthma and Allergic Rhinitis, run by University of South Florida at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 4 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: investigator closed study). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To determine if an overproduction of ANP is associated with atopy and asthma. (time frame: 1 YEAR). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Oct 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in